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ABSTRACT
Genomic integration by the Streptomyces bacter-
iophage rC31 integrase is a promising tool for
non-viral gene therapy of various genetic disorders.
We investigated the rC31 integrase recombination
activity in T cell derived cell lines, primary T lympho-
cytes and CD34
+ haematopoietic stem cells in com-
parison to mesenchymal stem cells and cell lines
derived from lung-, liver- and cervix-tissue. In T cell
lines, enhanced long-term expression above control
was observed only with high amounts of integrase
mRNA. Transfections of rC31 integrase plasmids
were not capable of mediating enhanced long-term
transgene expression in T cell lines. In contrast, mod-
erate to high efficiency could be detected in human
mesenchymalstem cells, human lung, liver and cervix
carcinoma cell lines. Up to 100-fold higher levels of
recombination product was found in rC31 integrase
transfected A549 lung than Jurkat T cells. When the
rC31 integrase activity was normalized to the intra-
cellular integrase mRNA levels, a 16-fold difference
was found. As one possible inhibitor of the rC31
integrase, we found 3- to 5-fold higher DAXX levels
in Jurkat than in A549 cells, which could in addition
to other yet unknown factors explain the observed
discrepancy of rC31 integrase activity.
INTRODUCTION
Promising clinical gene therapy trials have been underta-
ken recently to treat X-linked severe combined immuno-
deﬁciency (X-SCID) using replication-deﬁcient
retroviruses for gene delivery of the common cytokine
receptor g-chain (1,2). Autologous CD34
+ haematopoie-
tic stem cells were transduced ex vivo and retransfused into
patients, which led to a reconstitution of the bone marrow
and normal immune responses in 17 out of 20 treated
patients (3). However, out of 17 X-SCID patients, which
responded to the treatment, ﬁve patients developed T cell
leukaemia within 3 years after treatment due to insertional
mutagenesis (4–6). As an alternative to viral gene delivery
systems, non-viral gene therapy holds great promise for
the treatment of monogenetic diseases like X-SCID with-
out causing such assimilable severe side eﬀects. Though
transfection eﬃciency and transgene stability with non-
viral vectors still lags behind viral systems, new strategies
for genomic integration of the transgene have been devel-
oped, which reduce the risk of insertional mutagenesis
events (7). One such tool to achieve safe and stable non-
viral gene delivery is the Streptomyces bacteriophage
derived fC31 integrase, which mediates site-speciﬁc inte-
gration of plasmid DNA (pDNA) into mammalian host
genomes (8,9). We have recently shown that the fC31
integrase system could have potential for the treatment
of lung diseases, which was demonstrated by long-term
transgene expression in lung cells in vitro and in vivo with-
out selection pressure (10). Others have previously shown
recombination activity of the fC31 integrase and resulting
long-term transgene expression in tissues like murine liver
(9), rat retina (11) or human skin (12). So far there has
been only one study that addressed fC31 integrase activity
in haematopoietic cells. Ishikawa et al. (13) characterized
several known and new integration sites and observed
enhanced gene expression mediated by the fC31 integrase
in T cell derived Jurkat cell line under selection with G418.
The goal of this study was to compare the activity of the
fC31 integrase in the haematopoietic system with cells
derived from other tissues. One focus of our study was
to avoid application of cell-selection procedures, which
may not be applicable to clinical protocols. Though we
could conﬁrm that the fC31 integrase system is active in
haematopoietic cells, we could not observe any long-
term luciferase reporter gene expression mediated by
co-transfection of fC31 integrase expression plasmids.
Only co-delivery of high amounts of integrase mRNA
resulted in enhanced long-term transgene expression in
one T cell line. Moreover, the activity of fC31 integrase
for episomal recombination was low in any haematopoie-
tic cell type investigated. To determine if the fC31 integrase
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general, we examined primary haematopoietic cells and cell
lines in comparison with primary cells and cell lines of
various other tissues. We found that the activity of the
fC31 integrase is strongly cell type speciﬁc. Particularly in
haematopoietic cellsonly low activitywasobserved, whereas
in cells of all other tissues investigated moderate to high
activityof the fC31 integrase was detected. It has previously
been shown that DAXX protein interacts with the fC31
integrase and inhibits recombination (14). We further
detected higher amounts of DAXX protein in Jurkat T
cells than in A549 lung cells, which could be one reason for
the reduced fC31 integrase activity in haematopoietic cells.
MATERIALS AND METHODS
Plasmids
pCMVInt has been previously described (8,9,12) and was
kindly provided by M. P. Calos (Stanford University,
USA). pCAG-Int(NLS) and pPGK-Int(NLS) coding for
an integrase fused with a C-terminal nuclear localization
signal (NLS) of SV40T antigen, driven by CAG and PGK
promoters, respectively, and pSVpaxattP50-attB53, com-
prising an ‘expression blocking’ sequence ﬂanked by attB
and attP sites between a P1 promoter and a lacZ gene,
were kindly provided by R. Kuehn (Helmholtz Zentrum
Munich, German Research Centre for Environmental
Health, Germany). pC31-Intopt was obtained from
Addgene Inc. (Cambridge, MA, USA). pVAX1-Int was
constructed by excising the integrase cDNA from pCMV-
Int by PstI-XhoI (Fermentas, St. Leon-Rot, Germany)
digestion and cloning into respective sites of pVAX1
(Invitrogen, Paisley, UK). pdelCpG-GFP was obtained
from Geneart (GENEART AG, Regensburg, Germany)
and contains the same expression cassette as pVAX1 but
has reduced number of CpG motifs. The GFP expres-
sion cassette was removed from this plasmid by HindIII–
BamHI digestion and self-circularized to obtain pdelCpG.
Fragment containing the integrase was excised from
pVAX1-Int by PmeI digestion and cloned into PmeI site
of pdelCpG to generate pdelCpG-Int. mRNA coding
for the fC31 integrase was produced by CureVac
(CUREVAC GmbH, Tuebingen, Germany). pVAX1-Luc
was constructed as a shuttle vector by excising ﬁreﬂy luci-
ferase cDNA from pGL3-Basic vector (Promega, Madison,
WI, USA) by HindIII–XbaI digestion and cloning into the
corresponding sites of pVAX1. A HindIII–PmeI fragment
from pVAX1-Luc was then cloned into the same sites of
pdelCpG-GFP, thus replacing GFP with luciferase and gen-
erating pdelCpG-Luc. fC31 integrase recognition sequence
attB was excised from pTA-attB (provided by M. P. Calos)
by EcoRI digestion and was cloned blunt ended into the
BglII site of pdelCpG-Luc to obtain pdelCpG-Luc-attB.
pEGFPLucattB was kindly provided by T. W. Chalberg
(Stanford University, USA). Brieﬂy, the plasmid codes for
the fusion protein of EGFP and luciferase driven by the
CMV promoter and contains the attB recognition site
for the integrase in the plasmid backbone adjacent to the
ampicillin selection marker. All constructs used in this study
are schematically represented in Figure 1.
Cellculture
A549 (alveolar type II cells), HepG2 (hepatocytes), HeLa
(epithelial cervix carcinoma cells) and Jurkat (T cells) cell
lineswereobtainedfromGermanCollectionofMicroorgan-
isms and Cell Cultures (DSMZ - Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH, Braunschweig,
Germany). BEAS-2B (bronchial epithelia cells) cell line was
purchased from the ATCC (American Type Culture Collec-
tion, Rockville, MD, USA). Human primary CD3
+ Tc e l l s
were kindly provided by T. Magg (Ludwig-Maximilians-
University, Germany). Human primary mesenchymal stem
cells (Cambrex Corporation, East Rutherford, NJ, USA)
were kindly provided by C. Karow (Ludwig-Maximilians-
University, Germany) and grown in Dulbecco’s Modiﬁed
Eagle-Medium (PPA Laboratories, Linz, Austria) contain-
ing 10% fetal bovine serum (PPA Laboratories, Austria).
ED-7R cell line (15) was kindly provided by S. Kumaki
(Tohoku University, Japan). Umbilical cord blood sam-
ples were kindly provided by Bavarian Stem Cell Bank
(Bayerische Stammzellbank GmbH, Germany). Mono-
nuclear cells (MNC) were prepared from umbilical cord
blood and separated by Ficoll–Hypaque density gradient
centrifugation as described by Harris et al. (16). CD34
+
cells were further isolated from the initially separated
MNC by high-gradient magnetic sorting using Human
CD34 MultiSort Kit (MACS, Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany) following manufacturer’s
protocol. CD34
+ cells were grown in X-Vivo 10 (Cambrex
Corporation, USA) supplemented with SCF (20ng/ml;
Peprotech Inc, Rocky Hill, NJ, USA), TPO (50ng/ml;
Peprotech Inc, USA), human Flt-3 ligand (50ng/ml; Pepro-
tech Inc, USA). Human A549, BEAS-2B, HepG2 and
HeLa cells were grown in Minimum Essential Medium
(Gibco-BRL, Karlsruhe, Germany) containing 10% fetal
calf serum (PPA Laboratories, Austria). Jurkat, ED-7R
and human primary T cells were grown in RPMI 1640
Medium with Glutamax (Gibco-BRL, Germany) contain-
ing 10% fetal calf serum (PPA Laboratories, Austria).
All cells were maintained at 378Ci na5 %C O 2 humiﬁed
air atmosphere.
Transfections
1 10
6 A549, Jurkat, ED-7R, primary T cells, huHSC and
huMSC were transfected with nucleofection (Amaxa
Biosystems, Cologne, Germany) following manufactur-
er’s protocols using 5mg pDNA in total, respectively.
When transfections were performed with Metafectene
Pro (Biontex, Planegg, Germany) and Lipofectamin 2000
(Invitrogen, UK), 1 10
5cells per well were seeded in
24-well plates 24h prior the transfection. Metafectene
Pro was used with a total of 1mg pDNA in a ratio 4:1
(v/w) to transfect A549, BEAS-2B, HepG2, HeLa and
Jurkat cell lines as recommended by the manufacturer,
respectively. Lipofectamin 2000 was used to transfect
A549 cells with 1mg of pDNA in a ratio 2:1 (v/w).
Luciferase and b-galactosidaseassay
Twenty-four or 72h post-transfection cells were washed
twice with PBS followed by the addition of 100mlo f
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7.8). Cells were incubated for 10min at room temperature
in the lysis buﬀer. Ten microlitres of the lysate was used to
measure the protein amount by Bio-Rad protein assay
(BioRad, Munich, Germany) with a bovine serum albumin
standard. Fifty microlitres of the cell lysate was used
to measure luciferase activity or b-galactosidase on
aW a l l a cV i c t o r
2 1420 Multilabel Counter (Perkin Elmer,
Waltham, MA, USA), respectively. For measurement of
b-galactosidase activity, b-gal reporter gene assay kit
(Roche, Indianapolis, IN, USA) was used following
manufacturer’s protocol. Values were normalized with
respect to the protein concentration.
Westernblot analysis
Jurkat and A549 cells were gown in 6-well plates and trans-
fected with either pCMV-Int or pC31-Intopt by nucleo-
fection (as described earlier). Twenty-four hours after
transfection, Jurkat cells were washed once with PBS and
centrifuged by spinning at 300g for 5min. Medium was
aspirated from A549 cells and the cells were washed with
PBS, dislodged from the well bottoms by a rinsing with
200ml Trypsin–EDTA (Gibco-BRL, Germany), washed
with fresh PBS and Jurkat cell suspensions were pelleted
by spinning at 200g for 5min. Jurkat and A549 cells were
then lysed by adding 50ml of lysis buﬀer [0.15M sodium
chloride, 5mM EDTA, 1% Triton X-100, 100mM Tris–
HCl, 1M DTT, Complete
TM protease inhibitors (Roche,
USA); pH 7.4] After a 15min incubation on ice, lysates
were sonicated with a Digital Soniﬁer 250 (Branson,
Danbury, CT, USA) and cleared by 30min of centrifuga-
tion at 13 400 r.p.m. at 48C. For western blot analysis,
equal amounts of total protein were separated by elec-
trophoresis on 7.5% Tris–HCl gels (BioRad, Germany)
and transferred to polyvinylidene diﬂuoride membranes
(Millipore, Bedford, MA, USA). Membranes were incu-
bated either with anti-phiC31integrase rabbit pAb (kindly
provided by M. C. Smith, University of Aberdeen, UK) at a
1:2000 dilution or anti-DAXX mouse mAb (Biozol, Eching,
Germany) at a dilution of 1:100, respectively. As secondary
antibodies, either a goat anti-rabbit horseradish peroxidase
(HRP) conjugated antibody (BioRad, Germany) or a goat
anti-mouse HRP conjugated antibody (BioRad, Germany)
was utilized. Proteins were detected with the ECL chemilu-
minescence system (Amersham Biosciences, Piscataway,
NJ, USA).
Isolationof pDNA and analysis by PCR
Isolation of pDNA from mammalian cells was performed
by Qiaprep Spin Miniprep kit (Qiagen, Hilden, Germany)
following manufacturer’s protocol (News Qiagen Issue No.
2/95). The recombined plasmid product was detected by
PCR using Taq DNA polymerase (New England BioLabs,
Beverly, MA, USA) and the following primers: FPpuro
50-GCAAGGGTCTGGGCAGCG-30 and RPpuro 50-TT
GCCGATGTCGAGCCCG-30. One nanogram of the iso-
lated pDNA was used as template in the reaction. PCR
was performed using the following settings: 948C for 30s,
30 cycles with 948C for 30s, 608C for 20s, 728Cw i t h3 0s ,
followed by 728C for 5min.
Isolation of totalRNA, reverse transcription and
real-time quantitative PCR
Quantitative real-time PCR (qRT-PCR) was performed
to quantify recombination products. Ten nanogram of
isolated pDNA was used as template. The primers and
settings were the same as described earlier.
Total RNA was isolated by RNAeasy Mini Kit
(Qiagen, Germany) from Jurkat and A549 cells at speciﬁc
time-points after transfection, respectively. cDNA was
produced from 2mg total RNA using Superscript reverse
transcriptase (Invitrogen, UK) following the manufac-
turer’s protocol. qRT-PCR reactions were carried out in
a volume of 50ml. The following primers were used to
amplify integrase cDNA after transfection of pCMV-Int
and pC31-Intopt, respectively: FPint 50-ACAAGATATC
GTGACCGGGGTGGAC-30, RPint 50-TCCTCGAGCG
CCGCTACGTC-30, FPintopt 50-ATCACCGGCCTGTG
TAAGAG-30, RPintopt 50-CGTCGGGCTTCTTCTTGT
AG-30. An initial denaturation of 3min at 958C was fol-
lowed by 30 cycles with 958C for 30s, 628C for 20s and
728C for 90s. Two microlitres cDNA template was used
per reaction to quantify the integrase mRNA expression.
Speciﬁc primers were used to quantify DAXX: FP-
DAXX 50-GGACCCCACAAATGCAAACACTGC-30
and RP_DAXX 50-AGGGGATGCGCTCTATGACA
CG-30. Here, an initial denaturation of 3min at 958C
was followed by 30 cycles with 958C for 30s, 688C for
20s and 728C for 30s.
Of the cDNA template, 0.5ml was used per reaction to
quantify the DAXX mRNA expression, respectively.
Speciﬁcity of the PCR products was assessed by a melting
curve analysis and agarose electrophoresis.
Statistical methods
Results of multiple experiments are reported as
means S.D. Data were analysed using a two-tailed
paired Student’s t-test. Probability values P<0.05
(marked as asterisk) designated signiﬁcant diﬀerences
between test points.
RESULTS
Long-term gene expression after transfection of
haematopoietic Tcell lines
Jurkat T cells were co-transfected with diﬀerent constructs
coding for the fC31 integrase and pdelCpG-Luc-attB,
containing the attB sequence and a luciferase gene in a
CpG dinucleotide reduced backbone. The following inte-
grase constructs were tested: pCMV-Int, pdelCpG-Int,
pVAX1-Int, pPGK-Int(NLS) and pCAG-Int(NLS)
(Figure 1). pdelCpG was used as a negative control for
the integrase plasmids. These plasmids were co-transfected
with pdelCpG-Luc-attB in a ratio of 4:1 (w/w) using
nucleofection, which is an electroporation-based transfec-
tion method and has previously been shown to eﬃciently
transfect suspension cells (17–19). Co-transfection of
pDNA coding for the fC31 integrase compared to the
negative control pdelCpG (Figure 2A) or using
pdelCpG-Luc lacking attB could not signiﬁcantly enhance
5464 Nucleic Acids Research, 2008, Vol. 36, No. 17long-term luciferase expression in Jurkat cells (data not
shown). One of the reasons for the lack of long-term
gene expression may have been low integrase expression
levels. As it has previously been shown that mRNA trans-
fection in haematopoietic monocytes is more eﬃcient than
pDNA transfections (20), additional experiments were
performed using fC31 integrase mRNA instead of
pDNA. Using nucleofection, 0.5, 1.0 or 2.0mg of integrase
mRNA was co-transfected with 1mg pdelCpG-Luc-attB.
pdelCpG vector was used as negative control in these
experiments. With integrase mRNA, signiﬁcantly
enhanced long-term gene expression, compared to the
negative control, could be observed up to day 33 post-
transfection when a high amount (2mg) of integrase
mRNA was used (Figure 2B). We repeated these experi-
ments in another T cell line ED-7R, but in contrast
to Jurkat cells, transgene expression was not signiﬁcantly
diﬀerent from pdelCpG control transfections (Figure 2C).
Similar results were obtained when these long-term
expression experiments were repeated using electropora-
tion instead of nucleofection as gene delivery method,
using pEGFPLucattB instead of pdelCpG-Luc-attB or
using diﬀerent ratios of integrase plasmids to luc-attB
plasmid (data not shown).
Expression of rC31integrase protein
The expression studies in Jurkat and ED-7R cells sug-
gested either ineﬃcient integrase expression or low recom-
bination eﬃciency of the fC31 integrase to achieve
long-term gene expression in T cell lines. To conﬁrm the
expression of the integrase protein in the experimental
settings, Jurkat cells were transfected with either pCMV-
Int or the codon-optimized pC31-Intopt and western blot
analysis for the integrase protein was performed 24h post-
transfection. As positive control for the integrase expres-
sion constructs, A549 lung cells were transfected with the
same plasmids, a cell line in which it has previously been
Figure 1. Schematic representation of the pDNA constructs used in the present study.
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sion (10). Integrase speciﬁc bands for both constructs were
detected in A549 and Jurkat T cells, respectively, and
expression levels (either native or codon optimized) were
equivalent in each cell line (Figure 3A). Further, integrase
mRNA was quantiﬁed for pCMV-Int and pC31-Intopt
using qRT-PCR in both cell lines, respectively. The
pCMV-Int integrase mRNA level was signiﬁcantly
5.8-fold higher in A549 cells than in Jurkat cells
(Figure 3B), whereas no signiﬁcant diﬀerence was detected
for pC31-Intopt mRNA (Figure 3C).
Analysis ofthe rC31integrase function bymeasurement
of reporter gene activity ofepisomal recombination
products indifferent cell types
To specify whether the lack of integrase-mediated long-
term transgene expression in T cells lines was only due to
detection limits of luciferase or due to other yet unknown
cell speciﬁc reasons, we set up an episomal recombination
assay to investigate the fC31 integrase activity in more
detail. Various cell types were co-transfected with
pSVpaxattP50-attB53 and pdelCpG-Int or pCAG-Int
together with an internal transfection control
pEGFPLuc. The 7.2kb pSVpaxattP50-attB53 comprises
an ‘expression-blocking’ sequence ﬂanked by attB and
attP sites between the P1 promoter and the lacZ cDNA.
This ‘blocking’ sequence prohibits expression of b-galac-
tosidase. The fC31 integrase mediates the excision of the
‘blocking’ sequence and brings the promoter in frame with
the lacZ gene. Successful recombination results in a 6.1kb
recombined plasmid A, comprising the P1 promoter in
frame with the lacZ cDNA, which results in b-galactosi-
dase expression after transcription, and in a 1.1kb recom-
bined plasmid B, comprising the ‘blocking’ sequence. For
all experiments a negative control was performed using
pUC21 instead of the integrase plasmid. By subtracting
the pUC21 negative control background from the b-galac-
tosidase activity of the replicates, which were transfected
with the integrase pDNA, it is possible to calculate the
relative recombination eﬃciency of the fC31 integrase
in diﬀerent cell types in terms of active transcription
of the recombination product (plasmid A). Luciferase
activity in all experiments conﬁrmed successful transfec-
tions. b-galactosidase activity derived from plasmid A in
all non-haematopoietic cell lines indicated functionality of
the fC31 integrase, whereas no b-galactosidase activity
was measured in any of the haematopoietic cell types
(Figure 4A). The b-galactosidase expression was highest
in bronchial BEAS-2B cells, intermediate in liver HepG2
and HeLa cervix carcinoma cells and lowest in alveolar
type II A549 and huMSC cells, which suggests a cell type-
speciﬁc activity of the fC31 integrase. To exclude eﬀects
due to variations of the transfection eﬃciency, diﬀerent
transfection methods and integrase constructs were
investigated. A549 cells were co-transfected with
pSVpaxattP50-attB53, pEGFPLuc and pdelCpG-Int,
pCAG-Int(NLS) or pUC21, respectively, using either
nucleofection, Metafectene Pro or Lipofectamin 2000.
Although the transfection methods resulted in variations
of luciferase expressions ranging from low to high levels,
A
B
C
Figure 2. (A) Co-transfections of 1mg pdelCpG-Luc-attB and 4mg
integrase/control plasmids, respectively, were performed in Jurkat
cell line. No signiﬁcant long-term enhancement of luciferase activity
could be detected for the integrase constructs above pdelCpG control.
(B) Co-transfections of 1mg pdelCpG-Luc-attB and various amounts of
mRNA coding for fC31 integrase, respectively, were performed in
Jurkat cell line. Signiﬁcant enhancement of luciferase activity above
control could be detected at two time points for 2mg of integrase
mRNA. (C) Co-transfections of 1mg pdelCpG-Luc-attB and various
amounts of mRNA or diﬀerent plasmids coding for fC31 integrase,
respectively, were performed in ED-7R cell line. No luciferase activity
could be detected for any construct after day 10. Nucleofection was
used for all transfections. Luciferase values are relative to day 1 values.
All experiments were performed in ﬁve replicates (n=5).
5466 Nucleic Acids Research, 2008, Vol. 36, No. 17b-galactosidase activity derived from plasmid A could be
measured for pdelCpG-Int and pCAG-Int(NLS) and cor-
related with luciferase expression, in contrast to pUC21
control (data not shown). Therefore, the assay is indepen-
dent of the transfection method and the used integrase
construct.
Analysis ofthe rC31integrase function byPCR
detection of theepisomal recombination products in
different cell types
To investigate whether the observed lack of episomal
recombination in haematopoietic Jurkat T cells is due to
limitations of b-galactosidase activity detection of plasmid
A in the above used assay, or low activity of the fC31
integrase in haematopoietic Jurkat T cells, a PCR-based
assay was established to directly visualize the recombina-
tion product (plasmid B). Primers were designed, which
bind within the blocking sequence next to each other
and are ampliﬁed in opposite directions. This would
allow ampliﬁcation of a 0.94kb fragment of the smaller
recombination product (plasmid B) with a standard Taq
polymerase. In contrast, neither the large 6.1kb recombi-
nation product plasmid A nor the 7.2kb parental plasmid
could be ampliﬁed by a standard Taq polymerase because
of size constraints (>5kb). In case of successful recombi-
nation mediated by the fC31 integrase, a PCR fragment
of 0.94kb is expected. Whereas clear bands of the expected
0.94kb size could be detected in A549, BEAS-2B, HepG2
and HeLa cells transfected with the integrase construct
(pdelCpG-Int), only a very weak band was detected for
Jurkat cells (Figure 4B). As expected no bands could be
detected in the pUC21 negative controls in all samples.
The weak band indicated low activity of the fC31 inte-
grase in Jurkat cells.
Quantification of theepisomal recombination efficacy
ofthe rC31integrase in haematopoietic Jurkat
Tcells and A549 lungcells
A549 and Jurkat cells were chosen as model cell lines to
quantify the activity of the fC31 integrase in cells from
representative tissues. To achieve optimal integrase activ-
ity, pC31-Intopt, which is a highly eﬃcient integrase con-
struct due to a codon-optimized cDNA and a NLS (21),
was examined in comparison with pCMV-Int, which has
been used in most previous studies (8,13,22,23), and
pUC21 as a negative control. Metafectene Pro was used
as transfection reagent, which is capable of transfecting,
both A549 and Jurkat cells.
A
B C
Figure 3. (A) Cell lysates of either pCMV-Int transfected A549 and Jurkat cells or pC31-Intopt transfected A549 and Jurkat cells were analysed
by western blotting. Cell lysates of untreated A549 and Jurkat cells are represented. Detection of the integrase protein positive control is shown.
(B) Total RNA was isolated from A549 and Jurkat cells 24h post-transfection with pSVpaxattP50-attB53 and either pCMV-Int or (C) pC31-Intopt.
Total cDNA was produced by reverse transcriptase and integrase cDNA was quantiﬁed by qRT-PCR. The values represent the relative mRNA
integrase expression normalized to pCMV-Int in Jurkat cells 24h post-transfection.
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Intopt, b-galactosidase activity from plasmid A was
45-and265-foldhigher inA549thanin Jurkatcells, respec-
tively. After transfection of A549 cells with pCMV-Int,
b-galactosidase activity was 3- and 34-fold lower than
after transfection with pC31-Intopt 24 and 72h post-trans-
fection, respectively. Transfection of Jurkat cells with
pCMV-Int did not result in measurable b-galactosidase
activity from plasmid A (Figure 5A). No b-galactosidase
activity was observed in the negative pUC21 controls.
These observations demonstrate that episomal recombina-
tion can be principally observed by measurement of active
transcription of the recombination products in haemato-
poietic Jurkat cells by using a codon-optimized fC31
integrase.
However, in order to directly investigate episomal
recombination, the recombination products were further
analysed by PCR and qRT-PCR. A strong band of the
expected 0.94kb fragment of the recombination product
plasmid B was detected in A549 cells after transfection
with pCMV-Int and pC31-Intopt, whereas only a weak
band was observed in Jurkat cells 24h post-transfection
(Figure 5B). Twenty-four hours after transfection, qRT-
PCR resulted in statistically signiﬁcant 100- and 29-fold
B
A
Figure 4. (A) Triple transfections of pSVpaxattP50-attB53, an integrase
plasmid and pEGFPLuc were performed in various cell types. Activity of
fC31 integrase is shown as b-galactosidase activity per milligram pro-
tein. The mean   standard deviation of ratio of b-gal per protein (n=5)
is shown at 24h post-transfection. (B) pDNA was isolated from cells
transfected with pSVpaxattP50-attB53 and pdelCpG-Int or pUC21 con-
trol 24h post-transfection. Ampliﬁcation of a 0.94kb fragment of the
1.1kb recombined plasmid mediated by the functional fC31 integrase
was carried out by PCR. A549, BEAS-2B, HepG2, HeLa, Jurkat cells
co-transfected with pdelCpG-Int, respectively; A549, BEAS-2B, HepG2,
HeLa, Jurkat cells co-transfected with negative control pUC21, respec-
tively; H2O. Strong bands could be detected for all non-haematopoietic
cell types transfected with the integrase plasmid by gel electrophoresis,
whereas only a very weak band could be detected for Jurkat cell line.
pUC21 negative controls show no bands in any cell type.
Figure 5. (A) Triple transfections of pSVpaxattP50-attB53, pCMV-Int
or pC31-Intopt and pEGFPLuc were performed in A549 and Jurkat
cell lines. Activity of fC31 integrase is expressed as b-galactosidase
activity per milligram protein. The mean standard deviation of ratio
of b-gal per protein (n=5) is shown at 24 and 72h post-transfection.
(B) pDNA was isolated from A549 and Jurkat cells transfected with
pSVpaxattP50-attB53 and pCMV-Int, pC31-Intopt or pUC21 control
24h post-transfection. Ampliﬁcation of a 0.94kb fragment of the 1.1kb
recombined plasmid mediated by the functional fC31 integrase was
carried out by PCR. Jurkat cells co-transfected with pCMV-Int,
pC31-Intopt, pUC21, respectively; A549 cells co-transfected with
pCMV-Int, pC31-Intopt, pUC21, respectively; H2O. Strong bands
could be detected for A549 cells by gel electrophoresis, whereas only
weak bands could be detected for Jurkat cell line transfected with the
integrase plasmids. pUC21 negative controls show no bands in any cell
type.
5468 Nucleic Acids Research, 2008, Vol. 36, No. 17higher amounts of recombination product plasmid B in
A549 than in Jurkat cells for pCMV-Int and pC31-Intopt,
respectively. After 72h, 3- and 120-fold higher amounts of
recombination products were detected in A549 than in
Jurkat cells for pCMV-Int and pC31-Intopt, respectively
(Figure 6). Together with the measured mRNA levels after
transfection with pCMV-Int or pC31-Intopt (Figure 3B
and C), the fC31 integrase recombination eﬃcacy can be
normalized to the integrase mRNA levels for each of the
cell lines by dividing the amount of recombination product
plasmid B by the amount of integrase mRNA (Table 1). In
independent experiments with either pCMV-Int or pC31-
Intopt, a 17- and 16-fold higher normalized fC31 integrase
activity was observed in A549 than in Jurkat cells 24h post-
transfection, respectively (Table 2). These data demonstrate
that the fC31 integrase recombination eﬃcacy is markedly
reduced in haematopoietic Jurkat T cells compared with
lung cells.
Quantification of DAXX protein inhaematopoietic
JurkatTcells and A549 lungcells
DAXX protein has been previously shown to interact with
fC31 integrase and inhibit its recombination eﬃciency
(14). To investigate if cell type speciﬁc diﬀerences in the
amount of DAXX protein could be a likely reason for the
reduced activity of the fC31 integrase in T cells, western
blot analysis of DAXX protein in Jurkat and A549 cells
was carried out. Indeed, higher amounts of DAXX pro-
tein were observed in Jurkat than in A549 cells by semi-
quantiﬁcation of the western blot analysis (Figure 7A).
Figure 6. pDNA was isolated from A549 and Jurkat cells transfected
with pSVpaxattP50-attB53 and pCMV-Int, pC31-Intopt or pUC21
control 24 and 72h post-transfection was ampliﬁed and quantiﬁed by
qRT-PCR. The amount of recombination product Plasmid B of the
fC31 integrase is shown for A549 and Jurkat cells 24 and 72h post-
transfection. The values represent the amounts of recombination prod-
ucts normalized to pCMV-Int in Jurkat cells 24h post-transfection.
Table 1. fC31 integrase activity in Jurkat T and lung A549 cells
Cell
type
Time
point
(h)
b-galactosidase
activity
a
Amount of
recombination
product
plasmid B
b
Relative
integrase
mRNA
expression
c
pCMV-
Int
pC31-
Intopt
pCMV-
Int
pC31-
Intopt
pCMV-
Int
pC31-
Intopt
Jurkat 24 n.a.3 1 2 1 1
72 n.a. 1 1 0.3 n.a. 0.2
A549 24 49 149 100 55 5.8 1.7
72 8 265 5 36 1 2
aThe values represent the b-galactosidase activity normalized to pC31-
Intopt in Jurkat cells 72h post-transfection.
bThe values represent the amount of recombination product normalized
to pCMV-Int in Jurkat cells 72h post-transfection.
cThe values represent the integrase mRNA expression normalized to
pCMV-Int in Jurkat cells 24h post-transfection.
Table 2. Comparison of normalized fC31 integrase activity in Jurkat T
and lung A549 cells
Time point (h) pCMV-Int
a pC31-Intopt
b
24 17 16
72 n.a. 12
aThe values represent the ratio of the native integrase eﬃcacy (amount
of recombination product plasmid B/relative integrase mRNA expres-
sion) between A549 and Jurkat-cells.
bThe values represent the ratio of the codon-optimized integrase
eﬃcacy (amount of recombination product plasmid B/relative integrase
mRNA expression) between A549 and Jurkat cells.
Figure 7. (A) DAXX protein was detected 24 and 72h post-
transfections of CMV-Int in A549 and Jurkat cells by western blotting,
respectively. (B) Total RNA was isolated from A549 and Jurkat cells 24
and 72h post-transfection with pSVpaxattP50-attB53 and pCMV-Int.
Total cDNA was produced by reverse transcriptase and DAXX cDNA
was quantiﬁed by qRT-PCR.
Nucleic Acids Research, 2008, Vol. 36, No. 17 5469Further, qRT-PCR was performed to quantify DAXX on
mRNA level in A549 and Jurkat cells. The amounts of
DAXX were signiﬁcantly 2.7- and 5.4-fold higher in
Jurkat than in A549 cells 24 and 72h post-transfection,
respectively (Figure 7B).
DISCUSSION
It has previously been shown that the fC31 integrase from
the Streptomyces bacteriophage mediates integration of
transfected pDNA carrying attB sites into pseudo attP
sites of mammalian genomes. This process is relatively
site speciﬁc. Whereas other recombinases as Cre or Flp
also mediate excision (24), the recombination of the
fC31 is unidirectional resulting in only genomic integra-
tion (25). These properties give the fC31 integrase a great
potential for safe and long-term transgene expression.
The fC31 integrase has been shown to function in several
cell types and tissues, e.g. murine liver (9), murine and
human lung cells (10), human myoblasts (23) and human
T cell lines (13). Its functionality has been conﬁrmed by
analysis of genomic integration and by observation of
long-term expression of transgenes in the investigated cell
types. It has recently been shown that the integration spe-
ciﬁcity of the fC31 integrase is cell line dependent (26). To
investigate if the recombination eﬃciency of the fC31 inte-
grase is also cell type speciﬁc, we directly compared the
eﬃcacy of the fC31 integrase in cells from diﬀerent tissues
and could demonstrate cell-dependent integrase activity.
WeassessedthefeasibilityofthefC31integrasetomedi-
ate long-term gene expression in two human T cell lines
withoutapplicationofselectionpressure.Wecouldobserve
long-term luciferase expression above controls in Jurkat
cells only when using integrase mRNA instead of pDNA.
In a second T cell line, ED-7R no enhanced long-term
transgene expression could be observed. To investigate, if
theseﬁndingswereduetoalackofintegraseproteinexpres-
sion,westernblotanalysiswasperformedthatcouldclearly
detect the integrase protein in Jurkat cells after transfection
of integrase pDNA. To further exclude insuﬃcient sensi-
tivity of the luciferase detection method, we tested several
cell types from diﬀerent tissues under identical conditions
in a more sensitive episomal recombination assay.
Successful episomal recombination results in active tran-
scription of a b-galactosidase reporter plasmid, which
allows assessing recombination eﬃciency by b-galactosi-
dase measurement. Using this assay b-galactosidase activ-
ity could be clearly detected in A549 alveolar type II,
BEAS-2B bronchial epithelial, HepG2 hepatocytes and
HeLa epithelial cervix carcinoma cell lines, as well as, in
primary human mesenchymal stem cells, although the
b-galactosidase values varied up to 20-fold between
huMSC and BEAS-2B cells. However, neither Jurkat,
ED-7R, primary T lymphocytes nor primary human
CD34
+ haematopoietic progenitor cells showed any
b-galactosidase activityinrecombination assays. To exclude
variations due to P1 promoter dependent b-galactosidase
expression, we directly analysed fC31-mediated episomal
recombination by PCR ampliﬁcation of the recombination
product. In each of the transfected cells a PCR band of the
expected fragment couldbe observed, alsoinJurkat Tcells.
To investigate this eﬀect in further detail, we performed
additional experiments in A549 lung and Jurkat T cells.
In these experiments, in addition to pCMV-Int, we used
pC31-Intopt, a highly eﬃcient codon-optimized plasmid
coding for the fC31 integrase, which carries a C-terminal
NLS. As observed in the previous experiments, b-galacto-
sidase expression was not detected in Jurkat T cells for
pCMV-Int, but low b-galactosidase activity was found
with the highly eﬃcient pC31-Intopt in Jurkat cells,
although this was 50-fold lower than in A549 cells 24h
post-transfection. These observations demonstrate that in
principal the fC31 integrase is active in haematopoietic
cells but suggests that high levels of integrase are necessary
for successful recombination in these cells.
Unexpectedly, the amount of recombination product
plasmid B for pCMV-Int was 1.8-fold higher than for
pC31-Intopt in A549 cells 24h after transfection. The
lower amount of recombined pDNA for pC31-Intopt
compared to pCMV-Int may be explained by the NLS
in pC31-Intopt. The NLS apparently enhanced fC31 inte-
grase translocation into the nucleus, whereas a large frac-
tion of the pDNA remains in the cytoplasm, because the
nuclear membrane represents a limiting barrier for pDNA
to enter the nucleus (27). This may cause an adverse ratio
of cytoplasmatic pDNA to integrase protein in case of
pC31-Intopt compared to pCMV-Int, resulting in lower
amounts of initial recombination products. In contrast,
at the 72h time point after transfection 7.2-fold higher
levels of recombination products were found for pC31-
Intopt than pCMV-Int. This observation may be exp-
lained by the prolonged integrase expression from the
codon-optimized pC31-Intopt.
Furthermore, it has to be considered that the optimized
episomal plasmid-based assay used in this study does not
reﬂect inﬂuences of the chromatin structure and the
reduced homology of the pseudo attP sites in the mamma-
lian genome compared with wild-type attP site. Therefore,
the assay may overestimate the true recombination eﬃ-
cacy in the in vivo situation.
To further exclude hidden eﬀects due to low fC31 inte-
grase expression in Jurkat cells, we analysed the fC31 inte-
grase mRNA levels in both cell lines after transfection. The
integrase mRNA levels were used to normalize the inte-
grase recombination activity. For this purpose, the ratio
of recombination product plasmid B to integrase mRNA
was calculated. These calculations revealed a 16- and
17-fold higher recombination eﬃcacy in A549 than in
Jurkat cells for, both pCMV-Int and pC31-Intopt, respec-
tively. Together these observations indicate that the fC31
integrase activity is cell type speciﬁc.
It has previously been published that the cellular protein
DAXX interacts with fC31 integrase and inhibits its
recombination eﬃciency (14). We could detect higher
DAXX levels in Jurkat than in A549 cells by western blot
analysis, which suggests stronger integrase inhibition in
Jurkat cells and, therefore, a relative lower activity. To
strengthen this suggestion, we further quantiﬁed DAXX
on mRNA levels in both cell lines and could observe clear
diﬀerences 24 and 72h post-transfection. The signiﬁcantly
3-to5-foldhigherDAXXlevelsinJurkatcellsthaninA549
cells might cause the reduced activity due to interaction of
5470 Nucleic Acids Research, 2008, Vol. 36, No. 17DAXX with the fC31 integrase. However, other factors
are likely to be additionally involved in the interaction
with the fC31 integrase because the increase in DAXX
levels did not proportionally correlate with the reduction
of the normalized fC31 integrase eﬃcacy. It has to be
further investigated, which factors may be involved in
this interaction to explain cell type speciﬁcity of the fC31
integrase and how to overcome any of these interactions in
the haematopoietic T cells.
However, to successfully apply the fC31 integrase for
site-speciﬁc recombination in haematopoietic T cells with-
out the utilization of selection pressure, it may be suggested
that expression levels have to be largely increased. It may
be questioned if this can be achieved with non-viral gene
delivery systems without further fundamental improve-
ments. A conceivable future strategy could be the use of
either non-integrating lenti- and retro-viral vectors, which
transfect haematopoietic cells with high eﬃciencies, or
co-delivery of the recombinant fC31 integrase itself. In
particular, the later may be an attractive alternative for
the reason that it is independent of the intracellular tran-
scription and translation machinery and may, therefore,
allow to achieve high intranuclear fC31 integrase levels.
However, diﬃculties with successful protein transduction
will remain a challenging task which has to be carefully
addressed for this purpose.
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